Posted by Michael Wonder on 19 Aug 2019
AbbVie prices new rheumatoid arthritis drug at $59,000 a year
17 August 2019 - AbbVie has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drug maker struggling with rising competition for Humira, its blockbuster therapy for the same condition.
A four-week supply of Humira, the world’s best-selling medicine, has a list price of about $5,174, amounting to more than $60,000 for a year.
However, the list price is not necessarily what patients actually pay as “out-of-pocket” costs vary based on the duration of the treatment and individual health care plans.
